INmune Bio (INMB) has partnered with the Cell and Gene Therapy Catapult to establish large-scale, commercial-ready manufacturing for its cell therapy platforms. CGT Catapult is an independent technology and innovation organization specializing in the advancement of the cell and gene therapy industry. It was established by and works in partnership with Innovate UK. INmune Bio’s therapies harness the innate immune system to treat diseases including Alzheimer’s, prostate cancer, and recessive dystrophic epidermolysis bullosa, a rare genetic skin disorder. With active trials across the UK, Europe, Australia, Canada and the US, the company is advancing a diversified portfolio addressing significant unmet medical needs.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INMB:
- Inmune Bio Presents Alzheimer’s Trial Data at Conference
- Inmune Bio’s Promising Alzheimer’s Treatment and Growth Potential: A Buy Recommendation by Thomas Shrader
- Inmune Bio’s Promising Future: Buy Rating Backed by Key Data Releases and Innovative Approaches
- INmune Bio presents baseline demographics of participants in MINDFuL study
- INmune Bio’s Earnings Call: Key Insights and Future Prospects
